Pharmaceutical Raw Material Milrinone Powder Good Price CAS 78415-72-2

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Model NO.: Frazer-Milrinone
• Appearance: White Powder
• Shelf Life: 2 Years
• Storage: Keep in Cool and Dry Place
• Delivery: Express 5-7 Days Arrive
• Test Method: HPLC
• Assay: 99%
• MOQ: 1kg
• Shipping Area: Worldwide/All Countries
• CAS: 78415-72-2
• Mf: C12h9n3o
• MW: 211.219
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 200kg Per Month

Product Description

Pharmaceutical Raw Material Milrinone Powder Good Price CAS 78415-72-2

 

Specification of Analysis

ITEMS	SPECIFICATION	TESTRESULTS
Appearance	Off-white or white powder	Conforms
Identification	HPLC,NMR;LC-MS	Conforms
Related substances	Individual impurity≤0.5%	0.09%
	Total impurities≤1.0%	0.20%
Loss on drying	≤0.5%	0.3%
Residue on ignition	≤0.1%	0.04%
Heavy metals	≤10ppm	Conforms
Assay	≥98.0 %	99.1%

Description:

Milrinone, an inhibitor of phosphodiesterase selective for fraction III PDE, exerts a positive inotropic effect on the heart as well as a peripheral vasodilatory effect. Milrinone given intravenously produces significant improvements on cardiac output, pulmonary capillary wedge pressure and vascular resistance without significant effects on the heart rate.

Usage:

Milrinone, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival.